在印度南部的一个三级癌症中心治疗的早期乳腺癌患者的一周低分割辅助放疗:正向调强放疗(F-IMRT)和体积调弧治疗(VMAT)的比较剂量学研究。

IF 3 Q4 ONCOLOGY
International Journal of Breast Cancer Pub Date : 2025-06-28 eCollection Date: 2025-01-01 DOI:10.1155/ijbc/4267362
Ashwini Gopal, M L Prem Kumar, Prathusha Chitrala, Heena Kauser, A Krishnam Raju, V Sudhakar Kumar, Srilatha Cheera, P V Arun, N V N M Sresty, G Deleep Kumar
{"title":"在印度南部的一个三级癌症中心治疗的早期乳腺癌患者的一周低分割辅助放疗:正向调强放疗(F-IMRT)和体积调弧治疗(VMAT)的比较剂量学研究。","authors":"Ashwini Gopal, M L Prem Kumar, Prathusha Chitrala, Heena Kauser, A Krishnam Raju, V Sudhakar Kumar, Srilatha Cheera, P V Arun, N V N M Sresty, G Deleep Kumar","doi":"10.1155/ijbc/4267362","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> This study is aimed at comparing the forward IMRT (F-IMRT) and VMAT techniques in the adjuvant treatment of left-sided breast cancer using hypofractionated radiation over 1 week with deep inspiration breath hold (DIBH) via the Elekta Active Breathing Coordinator (ABC) system. <b>Materials and Methods:</b> Treatment plans for 26 patients receiving 26 Gy in five fractions (5.2 Gy/fraction), followed by a 10-Gy electron boost in five fractions, were analyzed. The boost phase was excluded from the comparison. F-IMRT and VMAT plans were evaluated for dose to 95% of the volume, conformity index (CI), mean left lung dose (MLLD), left lung V8 Gy, mean heart dose (MHD), heart V1.5Gy and V7Gy, mean right breast dose (MRBD), and mean right lung dose (MRLD). Statistical analysis was conducted using the Wilcoxon signed-rank test. <b>Results:</b> PTV coverage was similar in F-IMRT and VMAT arms (95.83% vs. 95.38%), but CI was significantly improved with VMAT (1.31 vs. 1.04). F-IMRT significantly reduced MLLD (4.55 Gy vs. 5.95 Gy) and left lung V8Gy (18.78% vs. 25.87%) when compared to VMAT. MHD was lower with F-IMRT (1.79Gy vs. 2.47Gy), with significantly reduced heart V1.5Gy (21.6% vs. 54.4%) when compared to VMAT, with V7Gy not different (5.04% vs. 5.79%) between F-IMRT and VMAT. F-IMRT also resulted in lower MRBD (0.62 Gy vs. 2.4 Gy) and MRLD (0.38 Gy vs. 1.8 Gy) when compared to VMAT. <b>Conclusion:</b> F-IMRT provides comparable target coverage to VMAT while significantly reducing radiation exposure to the heart, lungs, and contralateral breast for left-sided breast cancer treatment with DIBH and hypofractionation over 1 week. Given its dosimetric advantages, F-IMRT should be the preferred technique to enhance patient safety and minimize long-term toxicities.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2025 ","pages":"4267362"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228566/pdf/","citationCount":"0","resultStr":"{\"title\":\"One Week Hypofractionated Adjuvant Radiation for Early Breast Cancer Patients Treated at a Tertiary Cancer Centre in South India: A Comparative Dosimetric Study of Forward Intensity-Modulated Radiotherapy (F-IMRT) and Volumetric Modulated Arc Therapy (VMAT).\",\"authors\":\"Ashwini Gopal, M L Prem Kumar, Prathusha Chitrala, Heena Kauser, A Krishnam Raju, V Sudhakar Kumar, Srilatha Cheera, P V Arun, N V N M Sresty, G Deleep Kumar\",\"doi\":\"10.1155/ijbc/4267362\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> This study is aimed at comparing the forward IMRT (F-IMRT) and VMAT techniques in the adjuvant treatment of left-sided breast cancer using hypofractionated radiation over 1 week with deep inspiration breath hold (DIBH) via the Elekta Active Breathing Coordinator (ABC) system. <b>Materials and Methods:</b> Treatment plans for 26 patients receiving 26 Gy in five fractions (5.2 Gy/fraction), followed by a 10-Gy electron boost in five fractions, were analyzed. The boost phase was excluded from the comparison. F-IMRT and VMAT plans were evaluated for dose to 95% of the volume, conformity index (CI), mean left lung dose (MLLD), left lung V8 Gy, mean heart dose (MHD), heart V1.5Gy and V7Gy, mean right breast dose (MRBD), and mean right lung dose (MRLD). Statistical analysis was conducted using the Wilcoxon signed-rank test. <b>Results:</b> PTV coverage was similar in F-IMRT and VMAT arms (95.83% vs. 95.38%), but CI was significantly improved with VMAT (1.31 vs. 1.04). F-IMRT significantly reduced MLLD (4.55 Gy vs. 5.95 Gy) and left lung V8Gy (18.78% vs. 25.87%) when compared to VMAT. MHD was lower with F-IMRT (1.79Gy vs. 2.47Gy), with significantly reduced heart V1.5Gy (21.6% vs. 54.4%) when compared to VMAT, with V7Gy not different (5.04% vs. 5.79%) between F-IMRT and VMAT. F-IMRT also resulted in lower MRBD (0.62 Gy vs. 2.4 Gy) and MRLD (0.38 Gy vs. 1.8 Gy) when compared to VMAT. <b>Conclusion:</b> F-IMRT provides comparable target coverage to VMAT while significantly reducing radiation exposure to the heart, lungs, and contralateral breast for left-sided breast cancer treatment with DIBH and hypofractionation over 1 week. Given its dosimetric advantages, F-IMRT should be the preferred technique to enhance patient safety and minimize long-term toxicities.</p>\",\"PeriodicalId\":46159,\"journal\":{\"name\":\"International Journal of Breast Cancer\",\"volume\":\"2025 \",\"pages\":\"4267362\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12228566/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Breast Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/ijbc/4267362\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Breast Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijbc/4267362","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在比较前向IMRT (F-IMRT)和VMAT技术在通过Elekta主动呼吸协调器(ABC)系统使用低分割放疗辅助治疗左侧乳腺癌1周以上深度吸气屏气(DIBH)的效果。材料与方法:对26例患者分5段接受26 Gy (5.2 Gy/段)的治疗方案进行分析,然后再分5段进行10 Gy的电子增强。升压阶段被排除在比较之外。评估F-IMRT和VMAT计划的剂量至体积的95%、符合性指数(CI)、平均左肺剂量(MLLD)、左肺V8 Gy、平均心脏剂量(MHD)、心脏V1.5Gy和V7Gy、平均右乳剂量(MRBD)和平均右肺剂量(MRLD)。统计学分析采用Wilcoxon符号秩检验。结果:F-IMRT组和VMAT组的PTV覆盖率相似(95.83%比95.38%),但VMAT组的CI显著提高(1.31比1.04)。与VMAT相比,F-IMRT显著降低MLLD (4.55 Gy对5.95 Gy)和左肺V8Gy(18.78%对25.87%)。与VMAT相比,F-IMRT的MHD较低(1.79Gy对2.47Gy),心脏V1.5Gy显著降低(21.6%对54.4%),V7Gy在F-IMRT和VMAT之间无差异(5.04%对5.79%)。与VMAT相比,F-IMRT也导致较低的MRBD (0.62 Gy对2.4 Gy)和MRLD (0.38 Gy对1.8 Gy)。结论:F-IMRT提供了与VMAT相当的目标覆盖范围,同时在1周内显著减少了对心脏、肺和对侧乳房的辐射暴露,用于左侧乳腺癌DIBH和低分割治疗。鉴于其剂量学优势,F-IMRT应该是提高患者安全性和减少长期毒性的首选技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

One Week Hypofractionated Adjuvant Radiation for Early Breast Cancer Patients Treated at a Tertiary Cancer Centre in South India: A Comparative Dosimetric Study of Forward Intensity-Modulated Radiotherapy (F-IMRT) and Volumetric Modulated Arc Therapy (VMAT).

One Week Hypofractionated Adjuvant Radiation for Early Breast Cancer Patients Treated at a Tertiary Cancer Centre in South India: A Comparative Dosimetric Study of Forward Intensity-Modulated Radiotherapy (F-IMRT) and Volumetric Modulated Arc Therapy (VMAT).

One Week Hypofractionated Adjuvant Radiation for Early Breast Cancer Patients Treated at a Tertiary Cancer Centre in South India: A Comparative Dosimetric Study of Forward Intensity-Modulated Radiotherapy (F-IMRT) and Volumetric Modulated Arc Therapy (VMAT).

Objective: This study is aimed at comparing the forward IMRT (F-IMRT) and VMAT techniques in the adjuvant treatment of left-sided breast cancer using hypofractionated radiation over 1 week with deep inspiration breath hold (DIBH) via the Elekta Active Breathing Coordinator (ABC) system. Materials and Methods: Treatment plans for 26 patients receiving 26 Gy in five fractions (5.2 Gy/fraction), followed by a 10-Gy electron boost in five fractions, were analyzed. The boost phase was excluded from the comparison. F-IMRT and VMAT plans were evaluated for dose to 95% of the volume, conformity index (CI), mean left lung dose (MLLD), left lung V8 Gy, mean heart dose (MHD), heart V1.5Gy and V7Gy, mean right breast dose (MRBD), and mean right lung dose (MRLD). Statistical analysis was conducted using the Wilcoxon signed-rank test. Results: PTV coverage was similar in F-IMRT and VMAT arms (95.83% vs. 95.38%), but CI was significantly improved with VMAT (1.31 vs. 1.04). F-IMRT significantly reduced MLLD (4.55 Gy vs. 5.95 Gy) and left lung V8Gy (18.78% vs. 25.87%) when compared to VMAT. MHD was lower with F-IMRT (1.79Gy vs. 2.47Gy), with significantly reduced heart V1.5Gy (21.6% vs. 54.4%) when compared to VMAT, with V7Gy not different (5.04% vs. 5.79%) between F-IMRT and VMAT. F-IMRT also resulted in lower MRBD (0.62 Gy vs. 2.4 Gy) and MRLD (0.38 Gy vs. 1.8 Gy) when compared to VMAT. Conclusion: F-IMRT provides comparable target coverage to VMAT while significantly reducing radiation exposure to the heart, lungs, and contralateral breast for left-sided breast cancer treatment with DIBH and hypofractionation over 1 week. Given its dosimetric advantages, F-IMRT should be the preferred technique to enhance patient safety and minimize long-term toxicities.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.40
自引率
0.00%
发文量
25
审稿时长
19 weeks
期刊介绍: International Journal of Breast Cancer is a peer-reviewed, Open Access journal that provides a forum for scientists, clinicians, and health care professionals working in breast cancer research and management. The journal publishes original research articles, review articles, and clinical studies related to molecular pathology, genomics, genetic predisposition, screening and diagnosis, disease markers, drug sensitivity and resistance, as well as novel therapies, with a specific focus on molecular targeted agents and immune therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信